F
Fabrizio Stocchi
Researcher at Università telematica San Raffaele
Publications - 380
Citations - 20063
Fabrizio Stocchi is an academic researcher from Università telematica San Raffaele. The author has contributed to research in topics: Parkinson's disease & Levodopa. The author has an hindex of 62, co-authored 347 publications receiving 17268 citations. Previous affiliations of Fabrizio Stocchi include Medical Research Council & Icahn School of Medicine at Mount Sinai.
Papers
More filters
Journal ArticleDOI
The PRIAMO study: A multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease
Paolo Barone,Angelo Antonini,Carlo Colosimo,Roberto Marconi,Letterio Morgante,Tania P. Avarello,Eugenio Bottacchi,Antonino Cannas,Gabriella Ceravolo,Roberto Ceravolo,Giulio Cicarelli,Roberto M. Gaglio,Rosa M. Giglia,Francesco Iemolo,M. Manfredi,Giuseppe Meco,Alessandra Nicoletti,Massimo Pederzoli,Alfredo Petrone,Antonio Pisani,Francesco E. Pontieri,Rocco Quatrale,Silvia Ramat,Rosanna Scala,Giuseppe Volpe,Salvatore Zappulla,Anna Rita Bentivoglio,Fabrizio Stocchi,Giorgio Trianni,Paolo Del Dotto +29 more
TL;DR: A key role for NMS in the clinical frame of PD is supported and the need to address them specifically in clinical trials using dedicated scales is addressed.
Journal ArticleDOI
International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease : The NMSQuest study
Kallol Ray Chaudhuri,Pablo Martinez-Martin,Anthony H.V. Schapira,Fabrizio Stocchi,Kapil D. Sethi,Per Odin,Richard G. Brown,W. C. Koller,Paolo Barone,Graeme Macphee,Linda Kelly,Martin Rabey,Doug MacMahon,Sue Thomas,William G. Ondo,David B. Rye,A Forbes,S. Tluk,Vandana Dhawan,A Bowron,Adrian J. Williams,C. W. Olanow +21 more
TL;DR: An international pilot study assessing feasibility, validity, and acceptability of a nonmotor questionnaire (NMSQuest) found NMS were highly significantly more prevalent across all disease stages and the number of symptoms correlated significantly with advancing disease and duration of disease.
Journal ArticleDOI
The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.
Kallol Ray Chaudhuri,Pablo Martinez-Martin,Richard G. Brown,Kapil D. Sethi,Fabrizio Stocchi,Per Odin,William G. Ondo,Kazuo Abe,Graeme Macphee,Doug MacMahon,Paolo Barone,Martin Rabey,A Forbes,Kieran Breen,S. Tluk,Y. Naidu,Warren Olanow,Adrian J. Williams,Sue Thomas,David B. Rye,Yoshio Tsuboi,Annette Hand,Anthony H.V. Schapira,Anthony H.V. Schapira +23 more
TL;DR: NMSS can be used to assess the frequency and severity of NMS in PD patients across all stages in conjunction with the recently validated non‐motor questionnaire.
Journal ArticleDOI
A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
C. Warren Olanow,Olivier Rascol,Robert A. Hauser,Paul D. Feigin,Joseph Jankovic,Anthony E. Lang,William J. Langston,Eldad Melamed,Werner Poewe,Fabrizio Stocchi,Eduardo Tolosa +10 more
TL;DR: Early treatment with rasagiline at a dose of 1 mg per day provided benefits that were consistent with a possible disease-modifying effect, but early treatment with the two doses were associated with different outcomes, the study results must be interpreted with caution.
Journal ArticleDOI
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial
O. Rascol,David J. Brooks,Eldad Melamed,Wolfgang H. Oertel,W. Poewe,Fabrizio Stocchi,Eduard Tolosa +6 more
TL;DR: Once-daily rasagiline reduces mean daily off-time and improves symptoms of Parkinson's disease in levodopa-treated patients with motor fluctuations, an effect similar to that of entacapone.